EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer

Youngri Ryu, Eun Hye Kim, Hochung Jang, Yelee Kim, Byeongmin Park, Jiwoong Choi, Yeongji Jang, Sung-Gil Chi, Man Kyu Shim, Sun Hwa Kim, Hong Yeol Yoon, Yoosoo Yang iD

Small · 2025

DOI: 10.1002/smll.202504468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Youngri Ryu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, MicroRNAs, CD47 Antigen, Immunotherapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mid-Career Researcher Program, Korea Institute of Science and Technology, Intramural Research Program of the Korea Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks estrogen receptor, progesterone receptor, and HER2 expression, which limits the efficacy of targeted therapies. MicroRNA‐34a‐5p (miR‐34a), a tumor‐suppressor miRNA known for regulating oncogenic pathways, initially appeared promising as a therapeutic avenue. However, the clinical translation of miR‐34a has been hindered by challenges such as poor stability, inefficient cytoplasmic delivery, and immune‐related toxicities, as evidenced by the failure of MRX34 in trials. To address these limitations, this study developes a novel antibody‐oligonucleotide conjugate (AOC) platform anti‐CD47‐miR‐34a conjugate (aCD47‐C‐miR34a). The aCD47‐C‐miR34a system combines the anti‐CD47 antibodies with miR‐34a using a bioreducible linker, ensuring targeted cytoplasmic delivery via CD47‐mediated endocytosis and endosomal escape. CD47, an immune checkpoint protein overexpressed in TNBC, facilitates immune evasion, making it an attractive therapeutic target. In preclinical TNBC models, aCD47‐C‐miR34a successfully restored miR‐34a's tumor‐suppressive functions by downregulating oncogenic pathways including PD‐L1, while modulating the tumor microenvironment. This dual mechanism promoted macrophage phagocytosis, enhanced CD8 + T‐cell activation, and induced apoptosis, resulting in significant tumor inhibition without systemic toxicity. These findings demonstrate the transformative potential of aCD47‐C‐miR34a in overcoming TNBC's oncogenic and immune‐evasive mechanisms, paving the way for innovative treatments in TNBC and other heterogeneous, aggressive cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsMicroRNAsCD47 AntigenImmunotherapyImmunoconjugatesHumansAnimalsCell Line, TumorFemaleMice

Stichwörter der Autor:innen

TNBC immunotherapyantibody‐oligonucleotide conjugateendosomal escapemiRNA deliverymiR‐34a

Substanzen

MicroRNAsCD47 AntigenMIRN34 microRNA, humanImmunoconjugates

Autor:innen und Institutionen

  • Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
  • Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
  • KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.
  • Department of Life Sciences, Korea University, Seoul, 02841, Republic of Korea.
  • Division of Bio-Medical Science and Technology, KIST School, University of Science and Technology, Seoul, 02792, Republic of Korea.

ORCID-Profile: Yoosoo Yang

Förderung

  • Mid-Career Researcher Program
  • Korea Institute of Science and Technology
  • Intramural Research Program of the Korea Institute of Science and Technology
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Ryu, Y., Kim, E. H., Jang, H., Kim, Y., Park, B., Choi, J., Jang, Y., Chi, S. G., Shim, M. K., Kim, S. H., Yoon, H. Y., & Yang, Y. (2025). Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer. Small. https://doi.org/10.1002/smll.202504468

Vancouver

Ryu Y, Kim EH, Jang H, Kim Y, Park B, Choi J, et al. Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer. Small. 2025. doi:10.1002/smll.202504468

BibTeX
@article{Ryu2025,
  author = {Ryu, Youngri and Kim, Eun Hye and Jang, Hochung and Kim, Yelee and Park, Byeongmin and Choi, Jiwoong and Jang, Yeongji and Chi, Sung-Gil and Shim, Man Kyu and Kim, Sun Hwa and Yoon, Hong Yeol and Yang, Yoosoo},
  title = {Targeted Delivery of miR‐34a via Anti‐CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202504468}
}
Kostenlos starten →